<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03065374</url>
  </required_header>
  <id_info>
    <org_study_id>IMM592-EP1206</org_study_id>
    <nct_id>NCT03065374</nct_id>
  </id_info>
  <brief_title>Treatment for Clostridium-difficile Infection With IMM529</brief_title>
  <official_title>A Phase I/II, Randomized, Double Blind, Placebo-controlled Clinical Study of IMM529 for the Treatment of Clostridium-difficile Infection (CDI).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immuron Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immuron Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and tolerability of IMM-529 together with standard of&#xD;
      care (SOC) in patients with Clostridium-difficile Infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects who provide voluntary written informed consent will be screened for eligibility.&#xD;
      Subjects meeting all of the inclusion and none of the exclusion criteria will be eligible to&#xD;
      participate.&#xD;
&#xD;
      Eligible subjects will be randomized up to 3 weeks post diagnosis of Clostridium-difficile&#xD;
      Infection given SOC initiated already.&#xD;
&#xD;
      Each subject will return to the study clinic for assessment and required study procedures on&#xD;
      Day 7, Day 14, Week 4, Week 8 and Week 12 post randomization. Treatment duration will be 28&#xD;
      days and follow up will last up to 12 weeks post randomization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was stopped due to slow recruitment. All subjects completed their participation including&#xD;
    follow up period per protocol. No safety issues.&#xD;
  </why_stopped>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Actual">November 7, 2019</completion_date>
  <primary_completion_date type="Actual">November 7, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events incidence</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events severity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Severity of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>0, 7, 14 days and 4, 8, 12 weeks</time_frame>
    <description>Mortality rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease symptoms incidence</measure>
    <time_frame>0, 7, 14 days and 4, 8, 12 weeks</time_frame>
    <description>Time to resolution of symptoms defined by cessation of unformed stools</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease symptoms severity</measure>
    <time_frame>0, 7, 14 days and 4, 8, 12 weeks</time_frame>
    <description>Number of unformed stools per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Rate of subjects with recurring symptoms and positive stool test for C-Diff</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery rate</measure>
    <time_frame>4, 12 weeks</time_frame>
    <description>Stool sampling - neutralizing antibodies and spores and IMM-529 recovery rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <condition>Clostridium Difficile Infection Recurrence</condition>
  <arm_group>
    <arm_group_label>Treatment arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMM-529, 1000 mg three times daily, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo, three times daily, orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMM-529</intervention_name>
    <description>IMM-529</description>
    <arm_group_label>Treatment arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Treatment arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Unformed stools (≥3 loose stools in 24 hours at diagnosis)&#xD;
&#xD;
          3. Positive stool testing for C. difficile: PCR and Toxin B positive; or PCR and GDH&#xD;
             positive.&#xD;
&#xD;
          4. Up to 3 weeks of diagnosis with at least 20 subjects within 72 hours of diagnosis&#xD;
&#xD;
          5. Patient or legal representative must have read, understood, and provided written&#xD;
             informed consent after the nature of the study has been fully explained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of chronic diarrheal illness such as ulcerative colitis or Crohn's disease&#xD;
&#xD;
          2. Known concurrent severe organ insufficiency:&#xD;
&#xD;
             Liver: Decompensated cirrhosis (Any complication of cirrhosis or Child Score ≥7).&#xD;
&#xD;
             Cardiovascular: New York Heart Association (NYHA) class IV heart failure, or Ejection&#xD;
             fraction &lt;30%.&#xD;
&#xD;
             Respiratory: Severe exercise restriction (ie, unable to climb stairs or perform&#xD;
             household duties); chronic hypoxia, hypercapnia, severe pulmonary hypertension (&gt;40&#xD;
             mmHg); or respirator dependency Renal: Receiving chronic dialysis or GFR &lt; 15&#xD;
             mL/min/1.73m2&#xD;
&#xD;
          3. Other etiology of diarrhea.&#xD;
&#xD;
          4. Fulminant CDI, as defined by any of the following attributable to CDI:&#xD;
&#xD;
               1. Hypotension (Mean arterial pressure &lt; 65mmHg)&#xD;
&#xD;
               2. Ileus or significant abdominal distention&#xD;
&#xD;
               3. Toxic megacolon&#xD;
&#xD;
               4. End organ damage/failure:&#xD;
&#xD;
             Respiratory - Need for mechanical ventilation. Cardiac - Pulmonary edema. Renal -&#xD;
             Serum creatinine increase &gt;3x Baseline, GFR decrease &gt;50%, urinary output &lt;0.5mL/kg/hr&#xD;
             &gt; 12hrs. Hepatic - Liver failure (INR&gt;1.5, Hepatic encephalopathy), decompensation of&#xD;
             cirrhosis, bilirubin &gt; 2.5mg/dL.&#xD;
&#xD;
          5. Severe Clostridium difficile colitis with imminent surgery planned in less than 24&#xD;
             hours.&#xD;
&#xD;
          6. Immunocompromise due to: immunosuppressants, chemotherapy, radiation in the last 3&#xD;
             months, long-term steroids (&gt;10mg &gt;3 months) or high-dose steroids (&gt;40mg &gt; 3 weeks),&#xD;
             leukemia or lymphoma in the last 5 years, or HIV.&#xD;
&#xD;
          7. Any active malignancy within the last 5 years apart from localized skin cancer&#xD;
             (squamous cell carcinoma or basal cell carcinoma) that was fully excised.&#xD;
&#xD;
          8. Positive pregnancy test within 24 hours of study infusion or an unwillingness to&#xD;
             undergo pregnancy testing in females of child-bearing potential. Females capable of&#xD;
             child-bearing must agree not to become pregnant from the time of study enrollment&#xD;
             until at least 28 days after completion of study treatment period. If a woman is&#xD;
             sexually active and has no history of hysterectomy or tubal ligation, she must agree&#xD;
             to use 2 acceptable contraceptives (see section 7.4.1.) while participating in the&#xD;
             study and for 28 days following the last dose of study drug.&#xD;
&#xD;
          9. Breastfeeding&#xD;
&#xD;
         10. Receipt of other investigational study agent within previous 30 days.&#xD;
&#xD;
         11. Cow milk allergy, lactose intolerance or any known or suspected hypersensitivity to&#xD;
             study products&#xD;
&#xD;
         12. Any other condition that in the opinion of the investigator would jeopardize the&#xD;
             safety or rights of the patient participating in the study or make it unlikely the&#xD;
             patient could complete the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neta Tobis</last_name>
    <role>Study Chair</role>
    <affiliation>Immuron Limited</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jerry Kanellos</last_name>
    <role>Study Chair</role>
    <affiliation>Immuron Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Hospital</name>
      <address>
        <city>Tel HaShomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 14, 2017</study_first_submitted>
  <study_first_submitted_qc>February 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2017</study_first_posted>
  <last_update_submitted>December 24, 2019</last_update_submitted>
  <last_update_submitted_qc>December 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Enterocolitis, Pseudomembranous</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

